I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients

@article{Nguyen2004IVBI,
  title={I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients},
  author={Laurent Nguyen and David Fuller and S. Lennon and Fr{\'e}d{\'e}ric L{\'e}ger and Christian Puozzo},
  journal={Bone Marrow Transplantation},
  year={2004},
  volume={33},
  pages={979-987}
}
Summary:A retrospective population pharmacokinetic (PPK) analysis was performed in 24 pediatric patients (PEDS) (0.45–16.7 years old) receiving i.v. busulfan/cyclophosphamide (i.v. Bu/Cy 4) regimen prior to allogeneic hematopoietic stem cell transplantation. I.V. Bu doses were given as a 2-hour infusion every 6 h over 4 days. Initial dosing of i.v. Bu was 1 mg/kg for children ⩽4 years old and 0.8 mg/kg for patients >4 years old. Bu plasma concentrations at doses 1, 9 and 13 were analyzed… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 55 CITATIONS, ESTIMATED 53% COVERAGE

103 Citations

051015'07'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 103 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

Similar Papers

Loading similar papers…